Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc. filed an 8-K current report with the Securities and Exchange Commission on June 18, 2026, assigned accession number 0001808805-26-000027. The life sciences company, which focuses on proteomics and single-molecule protein sequencing technology, became publicly traded in 2021 following its business combination with ARYA Sciences Acquisition Corp III, a blank-check vehicle sponsored by ARYA Sciences Management. The 8-K represents a material-event disclosure from an operating company that completed its de-SPAC transition five years prior and continues to report under its post-merger structure. Sign up at SpacDesk for full filing histories, sponsor profiles, and deal analytics on Nautilus Biotechnology and hundreds of other SPAC-linked companies.